The expression of BAFF is controlled by IRF transcription factors

Journal of Immunology

Volumn 196, Issue 1, 2016, Pages 91-96

  Sjöstrand, Maria ^a   Johansson, Alina ^a   Aqrawi, Lara ^b   Olsson, Tomas ^a   Wahren Herlenius, Marie ^a   Espinosa, Alexander ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b UNIVERSITY OF BERGEN   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; B CELL ACTIVATING FACTOR; BETA1A INTERFERON; INTERFERON CONSENSUS SEQUENCE BINDING PROTEIN; INTERFERON REGULATORY FACTOR 1; INTERFERON REGULATORY FACTOR 2; INTERFERON REGULATORY FACTOR 4; BETA INTERFERON; INTERFERON REGULATORY FACTOR; INTERFERON REGULATORY FACTOR-4; IRF1 PROTEIN, HUMAN; IRF2 PROTEIN, HUMAN; TNFSF13B PROTEIN, HUMAN;

ARTICLE; B LYMPHOCYTE; BINDING SITE; CLINICAL ARTICLE; CONTROLLED STUDY; DOWN REGULATION; DRUG BLOOD LEVEL; DRUG MECHANISM; ENZYME REGULATION; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALE; MONOCYTE; MULTIPLE SCLEROSIS; NEUTROPHIL; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; SJOEGREN SYNDROME; SYSTEMIC LUPUS ERYTHEMATOSUS; BLOOD; CELL CULTURE; GENETIC TRANSCRIPTION; GENETICS; IMMUNOLOGY; MOLECULAR GENETICS; NUCLEOTIDE SEQUENCE;

AUTOANTIBODIES; B-CELL ACTIVATING FACTOR; B-LYMPHOCYTES; BASE SEQUENCE; BINDING SITES; CELLS, CULTURED; FEMALE; HUMANS; INTERFERON REGULATORY FACTOR-1; INTERFERON REGULATORY FACTOR-2; INTERFERON REGULATORY FACTORS; INTERFERON-BETA; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MOLECULAR SEQUENCE DATA; MONOCYTES; MULTIPLE SCLEROSIS; NEUTROPHILS; SJOGREN'S SYNDROME; TRANSCRIPTION, GENETIC;

EID: 84953210532     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1501061     Document Type: Article

References (25)

1. Bennett, L., A. K. Palucka, E. Arce, V. Cantrell, J. Borvak, J. Banchereau, and V. Pascual. 2003. Interferon and granulopoiesis signatures in systemic lupus erythematosus blood. J. Exp. Med. 197: 711-723.
2. Baechler, E. C, F. M. Batliwalla, G. Karypis, P. M. Gaffney, W. A. Ortmann, K. J. Espe, K. B. Shark, W. J. Grande, K. M. Hughes, V. Kapur, et al. 2003. Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus. Proc. Natl. Acad. Sci. USA 100: 2610-2615.
3. Brkic, Z., N. I. Maria, C. G. van Helden-Meeuwsen, J. P. van de Merwe, P. L. van Daele, V. A. Dalm, M. E. Wildenberg, W. Beumer, H. A. Drexhage, and M. A. Versnel. 2013. Prevalence of interferon type I signature in CD14 monocytes of patients with Sjogren's syndrome and association with disease activity and BAFF gene expression. Ann. Rheum. Dis. 72: 728-735.
4. Gottenberg, J. E., N. Cagnard, C. Lucchesi, F Letourneur, S. Mistou, T. Lazure, S. Jacques, N. Ba, M. Ittah, C. Lepajolec, et al. 2006. Activation of IFN pathways and plasmacytoid dendritic cell recruitment in target organs of primary Sjogren's syndrome. [Published erratum appears in 2006 Proc. Natl. Acad. Sci. USA. 103: 5242.] Proc. Natl. Acad. Sci. USA 103: 2770-2775.
5. Mavragani, C. P., and M. K. Crow. 2010. Activation of the type I interferon pathway in primary Sjogren's syndrome. J. Autoimmun. 35: 225-231.
6. Mackay, F, W. A. Figgett, D. Saulep, M. Lepage, and M. L. Hibbs. 2010. B-cell stage and context-dependent requirements for survival signals from BAFF and the B-cell receptor. Immunol. Rev. 237: 205-225.
7. Mariette, X., S. Roux, J. Zhang, D. Bengoufa, F Lavie, T. Zhou, and R. Kimberly. 2003. The level of BLyS (BAFF) correlates with the titre of autoantibodies in human Sjogren's syndrome. Ann. Rheum. Dis. 62: 168-171.
8. Varin, M. M., L. Le Pottier, P. Youinou, D. Saulep, F. Mackay, and J. O. Pers. 2010. B-cell tolerance breakdown in Sjogren's syndrome: focus on BAFF. Autoimmun. Rev. 9: 604-608.
9. Vincent, F. B., E. F. Morand, P. Schneider, and F. Mackay. 2014. The BAFF/ APRIL system in SLE pathogenesis. Nat. Rev. Rheumatol. 10: 365-373.
10. Dooley, M. A., F. Houssiau, C. Aranow, D. P. D'Cruz, A. Askanase, D. A. Roth, Z. J. Zhong, S. Cooper, W. W. Freimuth, and E. M. Ginzler, BLISS-52 and -76 Study Groups. 2013. Effect of belimumab treatment on renal outcomes: results from the phase 3 belimumab clinical trials in patients with SLE. Lupus 22: 63-72.
11. Mariette, X., R. Seror, L. Quartuccio, G. Baron, S. Salvin, M. Fabris, F Desmoulins, G. Nocturne, P. Ravaud, and S. De Vita. 2015. Efficacy and safety of belimumab in primary Sjogren's syndrome: results of the BELISS open-label phase II study. Ann. Rheum. Dis. 74: 526-531.
12. Sanz, I., U. Yasothan, and P. Kirkpatrick. 2011. Belimumab. Nat. Rev. Drug Discov. 10: 335-336.
13. Hedegaard, C. J., F Sellebjerg, M. Krakauer, D. Hesse, K. Bendtzen, and C. H. Nielsen. 2011. Interferon-beta increases systemic BAFF levels in multiple sclerosis without increasing autoantibody production. Mult. Scler. 17: 567-577.
14. Krumbholz, M., H. Faber, F Steinmeyer, L. A. Hoffmann, T Kiimpfel, H. Pellkofer, T. Derfuss, C. Ionescu, M. Starck, C. Hafner, et al. 2008. Interferon-beta increases BAFF levels in multiple sclerosis: implications for B cell autoimmunity. Brain 131: 1455-1463.
15. Moon, E. Y., and H. Park. 2007. B cell activating factor (BAFF) gene promoter activity depends upon co-activator, p300. Immunobiology 212: 637-645.
16. Woo, S. J., J. Im, J. H. Jeon, S. S. Kang, M. H. Lee, C. H. Yun, E. Y. Moon, M. K. Song, H. H. Kim, and S. H. Han. 2013. Induction of BAFF expression by IFN-7 via JAK/STAT signaling pathways in human intestinal epithelial cells. J. Leukoc. Biol. 93: 363-368.
17. Sjostrand, M., A. Ambrosi, S. Brauner, J. Sullivan, S. Malin, V. K. Kuchroo, A. Espinosa, and M. Wahren-Herlenius. 2013. Expression of the immune regulator tripartite-motif 21 is controlled by IFN regulatory factors. J. Immunol. 191: 3753-3763.
18. Groom, J., S. L. Kalled, A. H. Cutler, C. Olson, S. A. Woodcock, P. Schneider, J. Tschopp, T G. Cachero, M. Batten, J. Wheway, et al. 2002. Association of BAFF/BLyS overexpression and altered B cell differentiation with Sjogren's syndrome. J. Clin. Invest. 109: 59-68.
19. Cheema, G. S., V. Roschke, D. M. Hilbert, and W. Stohl. 2001. Elevated serum B lymphocyte stimulator levels in patients with systemic immune-based rheumatic diseases. Arthritis Rheum. 44: 1313-1319.
20. Ehret, G. B., P. Reichenbach, U. Schindler, C. M. Horvath, S. Fritz, M. Nabholz, and P. Bucher. 2001. DNA binding specificity of different STAT proteins. Comparison of in vitro specificity with natural target sites. J. Biol. Chem. 276: 6675-6688.
21. Ittah, M., C. Miceli-Richard, J. Eric Gottenberg, F. Lavie, T. Lazure, N. Ba, J. Sellam, C. Lepajolec, and X. Mariette. 2006. B cell-activating factor of the tumor necrosis factor family (BAFF) is expressed under stimulation by interferon in salivary gland epithelial cells in primary Sjogren's syndrome. Arthritis Res. Ther. 8: R51.
22. Gandhi, K. S., F. C. McKay, S. D. Schibeci, J. W. Arthur, R. N. Heard, G. J. Stewart, and D. R. Booth. 2008. BAFF is a biological response marker to IFN-beta treatment in multiple sclerosis. J. Interferon Cytokine Res. 28: 529-539.
23. Singh, M. K., T. F. Scott, W. A. LaFramboise, F. Z. Hu, J. C. Post, and G. D. Ehrlich. 2007. Gene expression changes in peripheral blood mononuclear cells from multiple sclerosis patients undergoing beta-interferon therapy. J. Neurol. Sci. 258: 52-59.
24. Shin, D. M., C. H. Lee, and H. C. Morse, III. 2011. IRF8 governs expression of genes involved in innate and adaptive immunity in human and mouse germinal center B cells. PLoS One 6: e27384.
25. Yao, Y, L. Richman, B. W. Higgs, C. A. Morehouse, M. de los Reyes, P. Brohawn, J. Zhang, B. White, A. J. Coyle, P. A. Kiener, and B. Jallal. 2009. Neutralization of interferon-alpha/beta-inducible genes and downstream effect in a phase I trial of an anti-interferon-alpha monoclonal antibody in systemic lupus erythematosus. Arthritis Rheum. 60: 1785-1796.